86.33p 0.0 0.0%
Last Trade - 3:16pm
| Market Cap | £459.9m |
| Enterprise Value | £514.9m |
| Revenue | £131.3m |
| Position in Universe | 597th / 1800 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 43.5 | 48.3 | 97.5 | 101.6 | 118.2 | 135.6 | 135.9 | 147.3 | +25.5% | ||
| -8.9 | -16.1 | +35.9 | +28.9 | -2.0 | +7.3 | -13.4 | +10.6 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international. The Company's therapeutic areas of focus include cardiovascular, central nervous system, child health, consumer health, dermatology, endocrinology, gastroenterology, obstetrics and gynecology, oral health, oncology, stoma care, toxicology and travel health. The Company's product categories include prescription only medicines, over the counter medications, medical devices, cosmetics and nutritional supplements. The Company's products include SkinSafe, Lift Plus, AbsorbaGel, DeoGel, LaVera, ClearWay, Gelclair, ImmuCyst 81mg, Hydromol, MacuShield, Lypsyl, Anbesol Adult Strength Gel, MolluDab and Ashton & Parsons Infants' Powders.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Incorporated | June 26, 2001 |
| Public Since | November 22, 2001 |
| No. of Shareholders: | n/a |
| No. of Employees: | 200 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Aim All Share , FTSE Aim 100 , FTSE Intl-aim UK 50 , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 532,919,111 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Avonbridge House Bath Road, CHIPPENHAM, SN15 2BB, United Kingdom |
| Web | https://www.alliancepharmaceuticals.com/ |
| Phone | +44 1249 466966 |
| Contact | () |
| Auditors | KPMG LLP |
As of 3:16pm, shares in Alliance Pharma are trading at 86.33p, giving the company a market capitalisation of £459.9m. This share price information is delayed by 15 minutes.
Shares in Alliance Pharma are currently trading at 86.33p and the price has moved by 4.86% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Alliance Pharma price has moved by 16.27% over the past year.
Of the analysts with advisory recommendations for Alliance Pharma, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Alliance Pharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Alliance Pharma is scheduled to issue upcoming financial results on the following dates:
The Alliance Pharma dividend yield is 0.62% based on the trailing twelve month period.
Last year, Alliance Pharma paid a total dividend of 0.01, and it currently has a trailing dividend yield of 0.62%. Looking ahead, Alliance Pharma has not announced an ex-dividend date yet.
Alliance Pharma has yet to annouce their ex-dividend date. The historic dividend yield on Alliance Pharma shares is currently 0.62%.
To buy shares in Alliance Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Alliance Pharma are currently trading at 86.33p, giving the company a market capitalisation of £459.9m.
Here are the trading details for Alliance Pharma:
Based on an overall assessment of its quality, value and momentum, Alliance Pharma is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Alliance Pharma are currently priced at 86.33p. At that level they are trading at 7.38% discount to the analyst consensus target price of 93.21.
Analysts covering Alliance Pharma currently have a consensus Earnings Per Share (EPS) forecast of 0.04487 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alliance Pharma. Over the past six months, the relative strength of its shares against the market has been 3.88%. At the current price of 86.33p, shares in Alliance Pharma are trading at 15.35% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Alliance Pharma PE ratio based on its reported earnings over the past 12 months is 17.51. The shares are currently trading at 86.33p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Alliance Pharma's management team is headed by:
Here are the top five shareholders of Alliance Pharma based on the size of their shareholding:
